Autres langues Enzymatica AB

Actions

ENZY

SE0003943620

Produits pharmaceutiques

Marché Fermé - Nasdaq Stockholm 18:00:00 02/10/2026			Varia. 5j.	Varia. 1 janv.
1,790 ^SEK	+3,17%		+7,51%	-5,79%

02/09	La directrice générale d'Enzymatica renforce sa participation	FW
01/09	La directrice générale d'Enzymatica acquiert 33 384 actions	FW

Autres langues

28/09	Notice of Extraordinary General Meeting in Enzymatica AB (publ)
27/08	Enzymatica strengthens its management team with commercial and scientific expertise
27/08	Enzymatica AB Announces Appointment of Bjarki Stefánsson as Chief Scientist and Head of Production Iceland
16/07	Enzymatica AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
16/07	Quarterly report Q2/2026 Continued focus on international expansion and a stronger organization
24/06	Enzymatica AB Provides Update On The Evidence Base For Coldzyme And PLOS ONE Expression Of Concern Regarding Berlin II Article
24/06	The evidence base for ColdZyme remains unchanged – PLOS ONE notice concerns the presentation of the Berlin II article, not the evidence base for ColdZyme
09/06	Enzymatica AB Announces Appointment of Joakim Tingström Nordin as Nordic Marketing and Sales Director, Effective August 2026
09/06	Enzymatica appoints Marketing and Sales Director to accelerate ColdZyme’s continued growth in the Nordics
08/06	Enzymatica : partners with Unibet Rose Rockets to put ColdZyme in the Giro d’Italia race routine
07/05	Bulletin from annual general meeting of Enzymatica AB (publ) on 7 May 2026
28/04	Enzymatica Q1 operating loss narrows to SEK 13.6 million
28/04	Quarterly report Q1/2026 - Enzymatica strengthens international position through STADA agreement
28/04	Enzymatica AB Reports Earnings Results for the First Quarter Ended March 31, 2026
14/04	Enzymatica publishes annual report for 2025
31/03	Enzymatica, Stada sign partnership agreement for Germany, Austria
31/03	Enzymatica and STADA sign partnership agreement for Germany and Austria
31/03	Enzymatica AB and Stada Arzneimittel Ag Sign Partnership Agreement for Launch and Distribution of Coldzyme Oral Spray Technology in Germany and Austria
31/03	Notice of Annual General Meeting 2026 in Enzymatica AB (publ)
18/02	Enzymatica AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
18/02	Enzymatica Q4 operating loss narrows SEK 10.2 mln
18/02	Year-end report 2025: New CEO takes the helm – initiates the next phase of Enzymatica’s international expansion
18/02	Year-end report 2025: New CEO takes the helm - initiates the next phase of Enzymatica's international expansion
18/02	Enzymatica AB Appoints Sana Alajmovic as Chief Executive Officer
11/12	Enzymatica Names Acting CFO